Reframe Daily: Many after mastectomy can skip radiation; antibody cuts kidney relapses; psoriasis pill works

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Two studies could shift care now—skipping radiation for many after mastectomy and using rituximab to prevent kidney relapses—while three early trials point to what’s next: a psoriasis pill, a Lassa fever vaccine, and an IL-6–targeting shot for knee arthritis.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

Good news: A common antibody medicine helped adults with hard‑to‑control nephrotic syndrome avoid relapses, which can mean fewer steroids and side effects.

Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial

Market readiness: 🙂🙂🙂🙂 (drug is already FDA‑approved for other conditions; clinicians can prescribe off‑label now while formal indication/coverage may follow). 

Good news: Many women with certain early breast cancers could safely skip chest‑wall radiation after mastectomy without hurting 10‑year survival—fewer treatments and fewer long‑term side effects.

Ten‑Year Survival after Postmastectomy Chest‑Wall Irradiation or No Irradiation in Patients with Early Breast Cancer

Market readiness: 🙂🙂🙂🙂 (evidence from a large phase 3 RCT; practice change can begin now as teams review data and guidelines update). 

Good news: An oral targeted peptide blocked the IL‑23 pathway and improved psoriasis in adults and teens—pointing to a future pill option instead of injections.

Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents

Market readiness: 🙂🙂🙂 (late‑stage clinical results but not FDA‑approved yet; regulatory review and possibly more trials ahead). 

Good news: A single‑dose rVSV Lassa fever vaccine was safe and triggered strong immune responses in a first‑in‑human trial—steady progress toward protection from a deadly viral disease.

Safety and Immunogenicity of an rVSV Lassa Fever Vaccine Candidate

Market readiness: 🙂🙂 (phase 1; needs larger phase 2/3 trials and licensure before use). 

Good news: A first‑in‑human “active immunotherapy” for knee osteoarthritis taught the body to tone down IL‑6 signaling, looked safe, and produced the expected immune response—hinting at a long‑lasting, disease‑modifying option.

Safety and immunogenicity of PPV‑06, an active anti‑IL‑6 immunotherapy targeting low‑grade inflammation against knee osteoarthritis: a randomized, double‑blind, placebo‑controlled, clinical phase 1 study

Market readiness: 🙂 (first‑in‑human phase 1; years of development remain).

Thank you for taking the time to take care of yourself and your loved ones.